Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: A cross-sectional study

British Journal of Cancer

Volumn 99, Issue 11, 2008, Pages 1929-1933

  Hibbitts, S ^a   Jones, J ^a   Powell, N ^a   Dallimore, N ^b   McRea, J ^c   Beer, H ^d   Tristram, A ^a   Fielder, H ^d   Fiander, A N ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d Screening Services   (United Kingdom)

Author keywords

Cervical cancer; HPV prevalence; Prophylactic HPV vaccine 'Cervarix '; Single and multiple HR cases

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; DYSKARYOSIS; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; UNITED KINGDOM; UTERINE CERVIX CANCER; VERRUCA VULGARIS; WART VIRUS;

ADULT; AGE DISTRIBUTION; AGED; CERVIX UTERI; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREVALENCE; SOCIOECONOMIC FACTORS; UTERINE CERVICAL NEOPLASMS; WALES;

EID: 56749164806     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604748     Document Type: Article

References (32)

1. Böhmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU (2003) No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 189: 118-120
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802
3. Breslow NE, Day NE (1987) The design and analysis of cohort studies. Statistical Methods in Cancer Research: Volume II 82: 1-406
4. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, IARC HPV Prevalence Surveys Study Group (2005a) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998
5. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM (2005b) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164
6. Cotton SC, Sharp L, Little J, Duncan I, Alexander L, Cruickshank ME, Gray NM, Jenkins D, Philips Z, Robertson A, Seth R, The TOMBOLA group (2006) Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): Trial design. Contemp Clin Trials 5: 449-471
7. Coupé VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ (2008) Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98(3): 646- 651
8. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E (2004) Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 57: 68-72
9. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362(9399): 1871-1876
10. de Sanjosé S, Bosch FX, Munoz N, Shah K (1997) Social differences in sexual behaviour and cervical cancer. IARC Sci Publ 138: 309-317
11. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7: 453-459
12. Department of Health News (2008) Department of Health awards contract for HPV vaccine, http://nds.coi.gov.uk/Content/Detail.asp?ReleaseID= 371095&NewsAreaID=2
13. Fife KH, Cramer HM, Schroeder JM, Brown DR (2001) Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol 64: 550-559
14. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765
15. Hibbitts S, Rieck GC, Hart K, Powell NG, Beukenholdt R, Dallimore N, McRea J, Hauke A, Tristram A, Fiander AN (2006) Human papillomavirus infection: an anonymous prevalence study in South Wales, UK. Br J Cancer 95: 226-232
16. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM (1997) A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35: 791-795
17. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574): 1693-1702
18. Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102: 3-8
19. Krieger N, Quesenberry Jr C, Peng T, Horn-Ross P, Stewart S, Brown S, Swallen K, Guillermo T, Suh D, Alvarez-Martinez L, Ward F (1999) Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988-92 (United States). Cancer Causes Control 10: 525-537
20. Muñoz N (2000) Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19: 1-5
21. National Assembly for Wales (2005) Welsh Index of Multiple Deprivation 2005. National Statistics Local Government Data Unit: Wales
22. NHS Cancer Screening Programmes (2004) Advice for cytopathology laboratories on the implementation of liquid based cytology for cervical screening. LBC Implementation Guide No 2 Version 1. Sheffield, UK
23. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA Study Group (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580): 2161-2170
24. Parikh S, Brennan P, Boffetta P (2003) Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 105: 687-691
25. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M (2004) Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91: 942-953
26. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC, ARTISTIC Study Group (2008) Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 98(10): 1704-1709. e-pub ahead of print
27. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632
28. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278
29. Vinokurova S, Wentzensen N, Einenkel J, Klaes R, Ziegert C, Melsheimer P, Sartor H, Horn LC, Höckel M, von Knebel Doeberitz M (2005) Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 97(24): 1816-1821
30. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19
31. Waterhouse J (2003) The European Standard Population (annex 5). World Health Annual of Statistics. Cancer Incidence in Five Continents. IARC WHO1976: Lyon 3: 456
32. Welsh Assembly Government News (2007) Vaccination against Cervical Cancer to be introduced in Wales, http://www.wales.nhs.uk/newsitem.cfm? contentid=7808